Efficacy and safety of alirocumab in statin-intolerant patients over 3 years: open-label treatment period of the ODYSSEY ALTERNATIVE trial.

导出 LinkOut

翻译打印收藏纠错

第一作者： Patrick M,Moriarty

第一单位： Division of Clinical Pharmacology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS, USA. Electronic address: pmoriart@kumc.edu.

作者： Patrick M,Moriarty ^[1] ; Paul D,Thompson ^[2] ; Christopher P,Cannon ^[3] ; John R,Guyton ^[4] ; Jean,Bergeron ^[5] ; Franklin J,Zieve ^[6] ; Eric,Bruckert ^[7] ; Terry A,Jacobson ^[8] ; Marie T,Baccara-Dinet ^[9] ; Jian,Zhao ^[10] ; Stephen,Donahue ^[11] ; Shazia,Ali ^[11] ; Garen,Manvelian ^[11] ; Robert,Pordy ^[11]

作者单位： Division of Clinical Pharmacology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS, USA. Electronic address: pmoriart@kumc.edu. ^[1] Hartford Hospital, Hartford, CT, USA. ^[2] Baim Institute for Clinical Research, Boston, MA, USA. ^[3] Duke University Medical Center, Durham, NC, USA. ^[4] Lipid Clinic, Centre Hospitalier Universitaire de Quebec, Laval University, Quebec, Canada. ^[5] McGuire VA Medical Center, Richmond, VA, USA. ^[6] Groupe Hospitalier Pitié-Salpêtrière (Assistance Publique-Hôpitaux de Paris), Paris, France. ^[7] Department of Medicine, Emory University, Atlanta, GA, USA. ^[8] Sanofi, Montpellier, France. ^[9] Regeneron Pharmaceuticals, Inc., Basking Ridge, NJ, USA. ^[10] Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA. ^[11]

关键词 Alirocumab Cholesterol-lowering drugs Efficacy PCSK9 Safety Statin

主题词老年人(Aged);胆固醇, LDL(Cholesterol, LDL);双盲法(Double-Blind Method);女(雌)性(Female);人类(Humans);羟甲基戊二酰基CoA还原酶抑制剂(Hydroxymethylglutaryl-CoA Reductase Inhibitors);高胆固醇血症(Hypercholesterolemia);男(雄)性(Male);中年人(Middle Aged);肌, 骨骼(Muscle, Skeletal)

DOI 10.1016/j.jacl.2020.01.001

PMID 32192644

发布时间 2021-12-04

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Journal of clinical lipidology

88-97.e2页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Efficacy and safety of alirocumab in statin-intolerant patients over 3 years: open-label treatment period of the ODYSSEY ALTERNATIVE trial.

Journal of clinical lipidology

相似文献

Journal of clinical lipidology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Efficacy and safety of alirocumab in statin-intolerant patients over 3 years: open-label treatment period of the ODYSSEY ALTERNATIVE trial.

Journal of clinical lipidology

相似文献

Journal of clinical lipidology

相关期刊

检索历史清除